Ers dechrau’r pandemig, rydym wedi bod yn gweithio’n agos gyda gwledydd eraill y DU i nodi a chyflwyno therapïau newydd ar gyfer trin COVID-19. Wrth benderfynu pa driniaethau y dylid eu defnyddio’n rheolaidd wrth reoli COVID-19 cawn arweiniad gan gyngor menter ymchwilio i lwybr mynediad ar gyfer cyffuriau ymchwiliol ar gyfer COVID-19 (RAPID C-19) a grŵp arbenigol clinigol cenedlaethol y DU ar therapiwteg COVID. Mae’r dull gweithredu hwn wedi gweithio’n dda i ni.
Since the start of the pandemic, we have worked closely with the other UK nations to identify and deploy novel therapies for the treatment of COVID-19.  In determining which treatments should be routinely used in the management of COVID-19 we are guided by the advice of the Research to access pathway for investigational drugs for COVID-19 (RAPID C-19) initiative and the UK national clinical expert group on COVID therapeutics.  This approach has served us well.